Latest news with #BSEHealthcare
Business Standard
4 days ago
- Business
- Business Standard
Astrazeneca Pharma India Ltd Spurts 7.28%
Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX Astrazeneca Pharma India Ltd gained 7.28% today to trade at Rs 8545.4. The BSE Healthcare index is up 0.34% to quote at 42749.54. The index is up 1.8 % over last one month. Among the other constituents of the index, Orchid Pharma Ltd increased 3.84% and Cohance Lifesciences Ltd added 1.94% on the day. The BSE Healthcare index went up 22.53 % over last one year compared to the 9.81% surge in benchmark SENSEX. Astrazeneca Pharma India Ltd has added 2.1% over last one month compared to 1.8% gain in BSE Healthcare index and 0.88% rise in the SENSEX. On the BSE, 1001 shares were traded in the counter so far compared with average daily volumes of 913 shares in the past one month. The stock hit a record high of Rs 9199 on 24 Apr 2025. The stock hit a 52-week low of Rs 5415.55 on 04 Jun 2024.
Business Standard
23-05-2025
- Business
- Business Standard
Windlas Biotech Ltd Slips 4.88%, BSE Healthcare index Shed 1.03%
Windlas Biotech Ltd has lost 9.89% over last one month compared to 1.44% fall in BSE Healthcare index and 1.1% rise in the SENSEX Windlas Biotech Ltd fell 4.88% today to trade at Rs 923. The BSE Healthcare index is down 1.03% to quote at 42080.34. The index is down 1.44 % over last one month. Among the other constituents of the index, Sun Pharmaceutical Industries Ltd decreased 4.08% and Indoco Remedies Ltd lost 3.58% on the day. The BSE Healthcare index went up 18.11 % over last one year compared to the 7.4% surge in benchmark SENSEX. Windlas Biotech Ltd has lost 9.89% over last one month compared to 1.44% fall in BSE Healthcare index and 1.1% rise in the SENSEX. On the BSE, 1506 shares were traded in the counter so far compared with average daily volumes of 5266 shares in the past one month. The stock hit a record high of Rs 1197 on 06 Nov 2024. The stock hit a 52-week low of Rs 552.85 on 04 Jun 2024.
Time of India
19-05-2025
- Business
- Time of India
DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy's Laboratories (DRL) has gained 5.5% on bourses in six trading sessions since declaring the fourth quarter numbers compared with a 3.6% increase in the BSE Healthcare index. The company reported double-digit growth in revenue and net profit for the March 2024 quarter. Revenue growth was driven by the acquisition of Nicotine Replacement Therapy (NRT) portfolio from UK's Haleon in June 2024. The next phase of growth once Revlimid sales taper after the drug goes off patent in January 2026, will be driven by biosimilars and Semaglutide portfolios. The company is likely to post double-digit revenue growth for FY26 but EBITDA margin may shrink to 25% from 28% in FY25 due to tapering sales of gRevlimid. Given this, analysts have reduced the target prices of the stock by 6-14%. Despite cuts, the target prices were 6-18% higher than the stock price on May 09 when the quarterly result was out and continue to remain above Monday's closing price of Rs1,219. Also, biosimilars and semaglutide offer future growth potential thereby supporting the stock price. On a year-on-year basis, DRL's revenue and net profit rose 20% and 21% year-on-year to Rs8,506 crore and Rs1,587 crore in the March 2025 quarter, respectively. Excluding NRT sales, revenue growth slowed to 12%. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased for the fifth consecutive quarter to Rs2,474.9 crore, a year-on-year 32.2% growth. Full-year R&D investment was Rs2,738 crores, up 20% year-on-year. However, its proportion in revenue fell by 118 basis points to 8.5%. The company expects to retain the R&D expenditure in a similar range even after the gRevlimid sales normalise. It will be driven by building a differentiated pipeline spanning small molecules, biosimilars, and complex generics including peptides and cancer therapy. DRL completed 95 global generic filings, bringing the total for FY25 to 249. The company is about to launch GLP-1 (Semaglutide) globally during the current calendar year. Abatacept, a medication used to treat rheumatoid arthritis and other autoimmune diseases, is into Phase III and the company plans to submit it for approval towards the end of 2025. The biosimilar segment remains a key growth driver in the coming quarters. According to Axis Securities, the company's two biosimilar drugs slated for launch in Europe have the potential to contribute $40–50 million in sales in FY26. Additionally, osteoporosis drug Denosumab, scheduled for launch in FY27, is estimated to generate $50 million in annual sales. The brokerage has cut the target price to Rs1,250 from Rs1,450 earlier, valuing the company at 17 times FY27 expected earnings. Elara Capital has lowered its FY26 earnings estimate 10% in anticipation of lower gRevlimid sales while raising FY27 estimate by 4% in anticipation of margin stability. The brokerage has highlighted price erosion in the US market and delay in product approvals as major risks to its forecast.
Economic Times
19-05-2025
- Business
- Economic Times
DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy's Laboratories (DRL) has gained 5.5% on bourses in six trading sessions since declaring the fourth quarter numbers compared with a 3.6% increase in the BSE Healthcare index. The company reported double-digit growth in revenue and net profit for the March 2024 quarter. Revenue growth was driven by the acquisition of Nicotine Replacement Therapy (NRT) portfolio from UK's Haleon in June 2024. The next phase of growth once Revlimid sales taper after the drug goes off patent in January 2026, will be driven by biosimilars and Semaglutide portfolios. ADVERTISEMENT The company is likely to post double-digit revenue growth for FY26 but EBITDA margin may shrink to 25% from 28% in FY25 due to tapering sales of gRevlimid. Given this, analysts have reduced the target prices of the stock by 6-14%. Despite cuts, the target prices were 6-18% higher than the stock price on May 09 when the quarterly result was out and continue to remain above Monday's closing price of Rs1,219. Also, biosimilars and semaglutide offer future growth potential thereby supporting the stock price. On a year-on-year basis, DRL's revenue and net profit rose 20% and 21% year-on-year to Rs8,506 crore and Rs1,587 crore in the March 2025 quarter, respectively. Excluding NRT sales, revenue growth slowed to 12%. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased for the fifth consecutive quarter to Rs2,474.9 crore, a year-on-year 32.2% growth. Full-year R&D investment was Rs2,738 crores, up 20% year-on-year. However, its proportion in revenue fell by 118 basis points to 8.5%. The company expects to retain the R&D expenditure in a similar range even after the gRevlimid sales normalise. It will be driven by building a differentiated pipeline spanning small molecules, biosimilars, and complex generics including peptides and cancer therapy. DRL completed 95 global generic filings, bringing the total for FY25 to company is about to launch GLP-1 (Semaglutide) globally during the current calendar year. Abatacept, a medication used to treat rheumatoid arthritis and other autoimmune diseases, is into Phase III and the company plans to submit it for approval towards the end of biosimilar segment remains a key growth driver in the coming quarters. According to Axis Securities, the company's two biosimilar drugs slated for launch in Europe have the potential to contribute $40–50 million in sales in FY26. Additionally, osteoporosis drug Denosumab, scheduled for launch in FY27, is estimated to generate $50 million in annual sales. The brokerage has cut the target price to Rs1,250 from Rs1,450 earlier, valuing the company at 17 times FY27 expected earnings. ADVERTISEMENT Elara Capital has lowered its FY26 earnings estimate 10% in anticipation of lower gRevlimid sales while raising FY27 estimate by 4% in anticipation of margin stability. The brokerage has highlighted price erosion in the US market and delay in product approvals as major risks to its forecast. (You can now subscribe to our ETMarkets WhatsApp channel)
Business Standard
13-05-2025
- Business
- Business Standard
Sun Pharmaceutical Industries Ltd Spurts 2.83%, BSE Healthcare index Rises 1.26%
Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX Sun Pharmaceutical Industries Ltd rose 2.83% today to trade at Rs 1733.95. The BSE Healthcare index is up 1.26% to quote at 42121.45. The index is up 4.26 % over last one month. Among the other constituents of the index, ERIS Lifesciences Ltd increased 2.7% and Aurobindo Pharma Ltd added 2.67% on the day. The BSE Healthcare index went up 20.02 % over last one year compared to the 13.3% surge in benchmark SENSEX. Sun Pharmaceutical Industries Ltd has added 2.75% over last one month compared to 4.26% gain in BSE Healthcare index and 9.71% rise in the SENSEX. On the BSE, 37402 shares were traded in the counter so far compared with average daily volumes of 58835 shares in the past one month. The stock hit a record high of Rs 1960.2 on 30 Sep 2024. The stock hit a 52-week low of Rs 1376.75 on 04 Jun 2024.
